Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) will release its third quarter 2025 financial results on November 3, 2025 after market close and will host an earnings conference call the same day at 4:30 PM ET. Management will provide a financial overview and business update for Q3 2025.
A live webcast will be available on Myriad’s Investor Relations website at investor.myriad.com. Telephone participants must register to receive a dial-in number and unique PIN. An archived webcast will be posted at investor.myriad.com following the call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MYGN declined 0.61%, reflecting a mild negative market reaction. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $754M at that time.
Data tracked by StockTitan Argus on the day of publication.
SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2025.
A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
When will Myriad Genetics (MYGN) release its Q3 2025 earnings and hold the conference call?
How can investors access the Myriad Genetics (MYGN) Q3 2025 earnings webcast?
Can I join the Myriad Genetics (MYGN) earnings call by phone and what is required?
What will Myriad management cover during the Q3 2025 earnings call for MYGN?
Where will the archived Myriad Genetics (MYGN) Q3 2025 earnings call be posted?
